Rivaroxaban, a Direct Oral Factor Xa Inhibitor, Attenuates Atherosclerosis by Alleviating Factor Xa–PAR2-Mediated Autophagy Suppression

The authors showed a mechanism for attenuating atherosclerosis by directly administering an oral factor Xa inhibitor (ie, rivaroxaban [RIV]). The autophagy activity of macrophages was significantly suppressed by factor Xa and was alleviated by the administration of RIV. However, factor Xa failed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Yusuke, Maejima, Yasuhiro, Nakagama, Shun, Shiheido-Watanabe, Yuka, Tamura, Natsuko, Sasano, Tetsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Preclinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733676/
https://www.ncbi.nlm.nih.gov/pubmed/35024502
http://dx.doi.org/10.1016/j.jacbts.2021.09.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733676/
https://www.ncbi.nlm.nih.gov/pubmed/35024502
http://dx.doi.org/10.1016/j.jacbts.2021.09.010

Ejemplares similares